Antibody titres decline 3-month post-vaccination with BNT162b2.
Antibody titres decline 3-month post-vaccination with BNT162b2.
复制标题
DOI：
10.1080/22221751.2021.1953403
复制
发表时间：
2021-12
影响因子：
13.2
通讯作者：
Douxfils J
中科院分区：
文献类型：
--
作者：
Favresse J;Bayart JL;Mullier F;Elsen M;Eucher C;Van Eeckhoudt S;Roy T;Wieers G;Laurent C;Dogné JM;Closset M;Douxfils J
几项研究报告了接受BNT 162 b2 mRNA COVID-19疫苗的受试者的体液反应。然而，目前缺乏关于疫苗接种后3个月抗体动力学的数据，这些数据对于推动未来的疫苗接种策略非常重要。CRO-VAX HCP研究是一项正在进行的多中心、前瞻性和干预性研究，旨在评估已接种两剂BNT 162 b2 mRNA COVID-19疫苗的医疗保健专业人员人群的抗体应答。200名受试者在首次接种疫苗前2天内接受了抽血。142人（71%）在基线时被归类为血清阴性，而58人（29%）为血清阳性。然后在14、28、42、56和90天后收集样品。在不同的时间点，在所有个体中测量针对SARS-CoV-2核衣壳和刺突蛋白S1亚基的受体结合结构域的抗体。使用一室动力学模型，估计至最大浓度的时间为首次给药后36 ± 3天，血清阴性受试者中抗体的估计半衰期为55天（95% CI：37-107天）。在血清阳性受试者中，至最大浓度的时间估计为24 ± 4天，估计半衰期为80天（95% CI：46-303天）。血清反应阳性者的抗体应答高于血清反应阴性者。在血清阳性和血清阴性受试者中，与峰值应答相比，在3个月时观察到抗体显著下降。然而，体液反应在所有参与者中仍然强劲。
Several studies reported on the humoral response in subjects having received the BNT162b2 mRNA COVID-19 vaccine. However, data on the kinetics of antibodies 3 months post-vaccination are currently lacking and are important to drive the future vaccination strategy. The CRO-VAX HCP study is an ongoing multicentre, prospective and interventional study designed to assess the antibody response in a population of healthcare professionals who had received two doses of the BNT162b2 mRNA COVID-19 vaccine. Two hundred individuals underwent a blood drawn within 2 days before the first vaccine dose. One-hundred and forty-two persons (71%) were categorized as seronegative at baseline while 58 (29%) were seropositive. Samples were then collected after 14, 28, 42, 56, and 90 days. Antibodies against the SARS-CoV-2 nucleocapsid and the receptor binding domain of the S1 subunit of the spike protein were measured in all individuals at different time points. Using a one-compartment kinetics model, the time to maximum concentration was estimated at 36 ± 3 days after the first dose and the estimated half-life of antibodies was 55 days (95% CI: 37–107 days) in seronegative participants. In seropositive participants, the time to maximum concentration was estimated at 24 ± 4 days and the estimated half-life was 80 days (95% CI: 46–303 days). The antibody response was higher in seropositive compared to seronegative participants. In both seropositive and seronegative subjects, a significant antibody decline was observed at 3 months compared to the peak response. Nevertheless, the humoral response remained robust in all participants.
登录
查看更多内容
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
抗SARS-COV-2受体结合结构域的血清阳性和血清效率医疗保健工人的总抗体反应正在接受COVID-19 MRNA BNT162B2疫苗接种。
DOI：
10.3390/diagnostics11050832
发表时间：
2021-05-04
期刊：
Diagnostics (Basel, Switzerland)
影响因子：
--
作者：
Salvagno GL;Henry BM;di Piazza G;Pighi L;De Nitto S;Bragantini D;Gianfilippi GL;Lippi G
通讯作者：
Lippi G
影响因子：
82.9
作者：
Ebinger JE;Fert-Bober J;Printsev I;Wu M;Sun N;Prostko JC;Frias EC;Stewart JL;Van Eyk JE;Braun JG;Cheng S;Sobhani K
通讯作者：
Sobhani K
DOI：
10.1016/j.cmi.2021.01.005
发表时间：
2021-01-20
期刊：
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
影响因子：
--
作者：
L'Huillier AG;Meyer B;Andrey DO;Arm-Vernez I;Baggio S;Didierlaurent A;Eberhardt CS;Eckerle I;Grasset-Salomon C;Huttner A;Posfay-Barbe KM;Royo IS;Pralong JA;Vuilleumier N;Yerly S;Siegrist CA;Kaiser L;Geneva Centre for Emerging Viral Diseases
通讯作者：
Geneva Centre for Emerging Viral Diseases
DOI：
10.1016/j.cca.2021.04.006
发表时间：
2021-08
期刊：
Clinica chimica acta; international journal of clinical chemistry
影响因子：
--
作者：
Padoan A;Dall'Olmo L;Rocca FD;Barbaro F;Cosma C;Basso D;Cattelan A;Cianci V;Plebani M
通讯作者：
Plebani M